SEC Tracker
Get the app

Eterna Therapeutics ERNA

Eterna Therapeutics FY 2024: revenue $582K, up 756%; diluted EPS −$3.26

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Eterna Therapeutics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$582K+756% from $68K in FY 202310-K income statement, on EDGAR
  2. Net income−$44.5MAgainst −$21.7M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$3.26Against −$4.08 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$1.7M−77% from $7.6M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$15.8MAgainst −$20.4M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Eterna Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Marker Therapeutics MRKR public float $17M, Jun 30, 2025
  2. Charlie's Holdings CHUC public float $18M, Jun 30, 2025
  3. Cognition Therapeutics CGTX public float $18M, Jun 30, 2025
  4. IGC Pharma IGC public float $18M, Jun 30, 2025
  5. Lipocine LPCN public float $16M, Jun 30, 2025